Voyager Therapeutics receives FDA clearance to begin Alzheimer's gene therapy trial

Filed June 1, 2026 · Period ending June 1, 2026 · ~1 min read

Key Changes

• high

  FDA cleared IND application for VY1706, an investigational gene therapy targeting tau protein in Alzheimer's disease, allowing human clinical trials to proceed

  Item 8.01 verify on EDGAR →
• high

  Company plans to begin dosing patients in second half of 2026 in multi-site Phase 1 trial, providing near-term clinical milestone

  Item 8.01 verify on EDGAR →
• medium

  Trial will enroll up to 18 early Alzheimer's patients across three dose cohorts, with primary focus on safety and secondary endpoints measuring tau biomarkers and brain imaging

  Item 8.01 verify on EDGAR →